All In Biotech

Drug Trial Radar · NCT01631214

Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

Last checked: Nov 20, 2026Latest source record: Feb 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,093 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,093

Actual

Start

May 4, 2012

Primary completion

Feb 27, 2017

Study completion Jun 29, 2017

Sponsor

Lead sponsor
AmgenAmgen (AMGN)
Sponsor type
Industry
First posted
Jun 29, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Female only, from 55 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if treatment is effective in preventing fractures in women with postmenopausal osteoporosis.

Conditions

  • Postmenopausal Women With Osteoporosis

Interventions

  • RomosozumabBiological

    Romosozumab 210 mg administered by subcutaneous injection once a month during the double-blind treatment phase.

  • AlendronateDrug

    Alendronate 70 mg tablet taken once a week

  • Placebo to RomosozumabDrug

    Administered by subcutaneous injection once a month during the double-blind treatment phase.

  • Placebo to AlendronateDrug

    Matching placebo tablet taken once a week during the double-blind treatment phase.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With New Vertebral Fractures Through Month 24Time frame: 24 months
  2. Percentage of Participants With a Clinical Fracture at the Primary AnalysisTime frame: The primary analysis was performed when clinical fracture events had been confirmed in at least 330 patients and all participants had completed the month 24 visit. The median follow-up was 2.7 years (interquartile range, 2.2 to 3.3).

Locations

316 sites in 42 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Peoria, Arizona

  • Research Site

    Phoenix, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Downey, California

  • Research Site

    Greenbrae, California

  • Research Site

    Los Angeles, California

  • Research Site

    South Lake Tahoe, California

  • Research Site

    Tustin, California

  • Research Site

    Walnut Creek, California

  • Research Site

    Lakewood, Colorado

  • Research Site

    Fort Lauderdale, Florida

  • Research Site

    Miami, Florida

  • Research Site

    Stuart, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Gainesville, Georgia

  • Research Site

    Maywood, Illinois

  • Research Site

    Quincy, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Bethesda, Maryland

  • Research Site

    Boston, Massachusetts

  • Research Site

    Detroit, Michigan

  • Research Site

    St Louis, Missouri

  • Research Site

    Las Vegas, Nevada

  • Research Site

    Las Cruces, New Mexico

  • Research Site

    Great Neck, New York

  • Research Site

    Bismarck, North Dakota

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Wyomissing, Pennsylvania

  • Research Site

    Richmond, Virginia

  • Research Site

    Port Angeles, Washington

  • Research Site

    Madison, Wisconsin

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Research Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Research Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

  • Research Site

    Mar del Plata, Buenos Aires, Argentina

  • Research Site

    Quilmes, Buenos Aires, Argentina

  • Research Site

    Córdoba, Córdoba Province, Argentina

  • Research Site

    Darlinghurst, New South Wales, Australia

Showing 40 of 316 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.